BURTONSVILLE, Md., Oct. 3, 2012 /PRNewswire/ -- ChiRhoClin, Inc. is pleased to notify the medical community that ChiRhoStim® (Human Secretin for Injection) has returned to the market. In cooperation with the FDA CDER Drug Shortage Team, ChiRhoClin is permitted to market the current batch of ChiRhoStim® until its new manufacturing site is operational by the beginning of 2013. ChiRhoStim® is an orphan drug product that aids in the diagnoses of pancreatic cancer and pancreatic exocrine dysfunction. ChiRhoStim® is approved for Pancreatic Function Testing, facilitating cannulation during ERCP, and Gastrinoma Testing. In addition, secretions of the pancreatic fluid after secretin stimulation can be used in situ for imaging modalities such as MRCP, CT, and EUS. Skip Purich, VP of Marketing and Operations, said, "One of ChiRhoClin's main goals is to generate grants to help fund pancreatic research for the medical community. With the release of ChiRhoStim®, researchers studying the pancreas now have a tool that can facilitate their research." ChiRhoClin is thankful to the FDA CDER Drug Shortage Team, pancreatic community, pharmacists, doctors, nurses, and especially the patients for their support and understanding during this drug shortage. ChiRhoClin, Inc., a Maryland based family run corporation founded in 1991 by Dr. Edward D. Purich, is a research and development oriented pharmaceutical company focused on developing orphan drug products for the gastrointestinal and radiological community. Our emphasis is to develop orphan drug products that will diagnose and treat pancreatic gastrointestinal diseases and encourage research in the pancreatic area through our small pancreatic grant program. If you would like more information on ChiRhoStim® (Human Secretin for Injection), please visit www.ChiRhoStim.com or call 301-476-8388. Skip Purich VP of Marketing and Operations ChiRhoClin, Inc. SOURCE ChiRhoClin, Inc.